The best kept secret

path forward

in drug development.

“Critical Path for Alzheimer’s Disease is helping the industry by developing the tools that can help optimize clinical trial designs, identify individuals best suited for trials, and understand what are meaningful benefits for those diagnosed with early symptoms of AD. We need that perspective.”

Joe Montminy

Person Living with Younger-Onset Alzheimer's and Advocate for All People Living with Dementia

“Being a scientist, sometimes when you talk to people in other realms, it’s like speaking a different language. C-Path and the T1D Consortium is translating a lot of science talk into something actionable for those who are making decisions and can actually push these types of initiatives forward.”

Ryan Eberwine

Drug Discovery and Development Scientist, Person Living with T1D

“I hope that the Duchenne Regulatory Science Consortium (D-RSC) becomes more well known, and that everybody knows what kind of work they’re doing. I see a bright future ahead, and I see things being more accessible with the help of D-RSC. For anyone reading this, know that you can make a difference.”

Ryan Russell

PhD, Life Coach, Person Living with Duchenne Muscular Dystrophy

“Working with C-Path gives me so much hope because for the last 4.5 years of my advocacy and involvement in ALS Research and Clinical trial design, I’ve seen so many efforts that are disconnected and fragmented. Now I see this collaboration advancing therapeutic development for our disease.”

Phil Green

Person Living with ALS, Patient Advocate

“My initial impression of CP-RND is that it’s a fantastic opportunity for the ALS Community and others to play an important part in what I would call a dream team of the FDA, NIH, C-Path and patients that’s focused on accelerated development of powerful natural history data.”

Ron Bartek

Co-founder/President, Friedreich’s Ataxia Research Alliance